The Chemistry of Medicines
Medicines — from ancient herbal remedies to modern targeted therapies — are chemical substances that interact with biological systems to prevent, diagnose, or treat disease. Pharmaceutical chemistry bridges organic synthesis, biochemistry, molecular biology, and pharmacology to design molecules that achieve therapeutic effects with minimal side effects.
How Drugs Work: Molecular Targets
Most drugs work by interacting with specific biological macromolecules called targets — typically proteins. The major target classes are:
- Receptors — Membrane or intracellular proteins that bind signaling molecules. Drugs can be agonists (mimicking the natural ligand to activate the receptor) or antagonists (blocking the binding site to prevent activation). Beta-blockers like atenolol are antagonists at beta-adrenergic receptors, reducing heart rate and blood pressure.
- Enzymes — Catalytic proteins. Drugs can be competitive inhibitors (competing for the active site) or irreversible inhibitors (covalently modifying the enzyme). Aspirin irreversibly acetylates cyclooxygenase (COX), blocking prostaglandin synthesis and reducing pain and inflammation.
- Ion channels — Transmembrane pores that control ion flow. Local anesthetics like lidocaine block sodium channels in nerve cells, preventing pain signal transmission.
- Transporters — Proteins that shuttle molecules across membranes. SSRIs (selective serotonin reuptake inhibitors, e.g., fluoxetine) block the serotonin transporter, increasing serotonin levels in synapses.
The "lock-and-key" model and its refinement, the induced-fit model, describe how a drug molecule must complement the shape, charge distribution, and hydrogen-bonding pattern of its target's binding site. Small changes in molecular structure can dramatically alter binding affinity and selectivity.
Drug Design and Structure-Activity Relationships
Modern drug design relies on structure-activity relationships (SAR) — systematically modifying a molecule's structure and measuring the effect on biological activity. Medicinal chemists manipulate:
- Functional groups — Adding or removing hydroxyl, amino, methyl, or halogen groups changes polarity, solubility, and binding interactions.
- Stereochemistry — Many drug targets are chiral, so enantiomers (mirror-image molecules) can have vastly different effects. The (S)-enantiomer of ibuprofen is the active anti-inflammatory form; the (R)-enantiomer is largely inactive and slowly converted to (S) in vivo. Thalidomide notoriously demonstrated the danger of ignoring chirality: one enantiomer was a sedative, while the other caused severe birth defects.
- Molecular size and shape — Computer modeling (molecular docking, molecular dynamics) predicts how well a candidate molecule fits the target binding site.
Aspirin: A Case Study in Drug Chemistry
Aspirin (acetylsalicylic acid) is perhaps the most studied drug in history. Its story illustrates key pharmaceutical chemistry principles:
Origins: Hippocrates used willow bark (containing salicin) for pain relief around 400 BCE. In 1897, Felix Hoffmann at Bayer synthesized acetylsalicylic acid by acetylating the hydroxyl group of salicylic acid with acetic anhydride:
Salicylic acid + Acetic anhydride -> Acetylsalicylic acid + Acetic acid
This acetylation solved a practical problem: salicylic acid was effective but caused severe stomach irritation. The acetyl group reduces acidity (pKa rises from 3.0 to 3.5) and is hydrolyzed in the body to release salicylate.
Mechanism: Aspirin irreversibly transfers its acetyl group to a serine residue (Ser530) in the active site of cyclooxygenase-1 and cyclooxygenase-2 (COX-1, COX-2). This permanently blocks the enzyme's ability to convert arachidonic acid to prostaglandins and thromboxanes. The anti-platelet effect (preventing heart attacks) comes from COX-1 inhibition in platelets, which cannot synthesize new enzyme because they lack nuclei.
Pharmacokinetics: ADME
A drug must reach its target at the right concentration for the right duration. Pharmacokinetics describes four processes:
- Absorption — How the drug enters the bloodstream. Oral drugs must survive stomach acid (pH 1-2), dissolve, cross the intestinal epithelium (typically by passive diffusion for lipophilic molecules), and survive first-pass metabolism in the liver.
- Distribution — How the drug spreads through the body. Lipophilic drugs cross the blood-brain barrier more readily. Protein binding (e.g., to albumin) acts as a reservoir, slowing distribution.
- Metabolism — Enzymatic transformation of the drug, primarily in the liver by cytochrome P450 enzymes. Phase I reactions (oxidation, reduction, hydrolysis) introduce or expose functional groups. Phase II reactions (conjugation with glucuronic acid, sulfate, glutathione) increase water solubility for excretion.
- Excretion — Elimination of the drug and its metabolites, primarily via the kidneys (urine) or liver (bile/feces).
Lipinski's Rule of Five provides guidelines for predicting oral bioavailability: molecular weight under 500 Da, no more than 5 hydrogen-bond donors, no more than 10 hydrogen-bond acceptors, and a calculated logP (octanol-water partition coefficient) under 5. While many successful drugs violate one or more of these rules, they remain a useful starting filter.
Antibiotics: Exploiting Chemical Differences
Antibiotics selectively target bacterial processes that differ from human biochemistry:
- Beta-lactams (penicillins, cephalosporins) inhibit bacterial cell-wall synthesis by covalently binding to transpeptidase enzymes. Human cells lack cell walls, ensuring selectivity.
- Tetracyclines bind the bacterial 30S ribosomal subunit, blocking protein synthesis. They are selective because bacterial and human ribosomes differ structurally.
- Fluoroquinolones (ciprofloxacin) inhibit bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication that have no close human analogue.
Antibiotic resistance arises through mutations (altering the drug target), enzymatic degradation (beta-lactamases that cleave penicillin's beta-lactam ring), efflux pumps (actively expelling the drug), and reduced permeability. This arms race drives the ongoing need for new antibiotics — a challenge that pharmaceutical chemistry continues to confront.